Exact Sciences

Family Centers is a non-profit organization that offers education, health care, and human services to children and adults.

Axis Community Health provides public health care services.

Crossroad Health Center specializes in primary health care and mental health counseling for Over-the-Rhine and surrounding communities of Cincinnati. In five locations throughout Greater Cincinnati, they provide medical services to 11,000 children and adults regardless of their insurance status or ability to pay. Their mission is to honor Jesus Christ by providing accessible, comprehensive health care in partnership with their patients and community that transforms lives. Compassion and dignity are applied to the whole person - body, mind, and spirit.

Chiricahua Community Health Centers is a mission-driven Federally Qualified Health Center [tax exempt not-for-profit 501(c)3] founded as a grassroots community effort in 1996. Beginning as a makeshift clinic in a rural town’s small community center, They have since grown to be the primary care organization in southeastern Arizona.

Five Rivers Health Centers provides primary healthcare, pediatric, dental, and behavioral services.

FDRHPO collaborates with several local hospitals, care offices, and community-based organizations to find and fill gaps in the healthcare system. They offer to identify and frame research questions, identify appropriate populations, design surveys, focus groups, or other research methods, and collect data using practices.

Harbor Community Health Centers is a health care service provider for men, women, and children. Their services include preventive options like routine and school and sports physicals, immunizations, ob and gyn care, and health screenings, as well as treatment of both acute and chronic illnesses and diseases.

Generations Family Health Center is a healthcare institution that offers telemedicine, medical procedures and dental services.

CommWell Health delivers culturally sensitive, linguistically appropriate, full life cycle primary, preventative, behavioral, and oral health care and enabling and care coordination/health coach services. Their goal and commitments are to help their communities get and stay healthy. Since opening its doors, the organization has been an integral part of the health care of communities. They represent wellness and health as its primary focus and consider the communities it serves as its waiting room.

IPHA is a non-profit organization that provides health advocacy, health education, and public health programming services.

The Jane Pauley Community Health Center provides healthcare, dental, and behavioral health services.

KC CARE Health Center provides quality care, access, research, and education to the underprivileged and all people.

Ozarks Community Health Center provides behavioral health, medical and dental care, obstetrics, and gynecological treatment solutions.

Rural Wisconsin Health Cooperative provides coding, legal, speech, audiology, education and work development services.

Southwest Community Health Center provides medical care for dental, mental health, substance abuse and gynaecological issues.

The Centers offer integrated healthcare, wellness, early learning, family support and workforce development services.

WCHQ is a multi-stakeholder, voluntary consortium of Wisconsin organizations. WCHQ draws its membership from health systems, medical groups, hospitals and health plans. This diverse and dynamic group includes the state's largest health systems, Aurora Health Care and the University of Wisconsin Hospital and Clinics / University of Wisconsin Medical Foundation.

Lone Star Circle of Care is a federally qualified community health center and a non‐profit organization operating health clinics in Texas.

Marshall Medical Center is a nonprofit healthcare service provider company.

Optimus Health Care is a non-profit organization their medical services include behavioral health, primary care, and women’s health services. Dental services include adult and pediatric dental services. Specialty care services include acupuncture, general surgery, ophthalmology, asthma care, geriatrics, podiatry, chiropractic, naturopathic, obstetrics, and gynecology. Acupuncture services include skilled, individualized treatments to relieve pain and stress, bring emotional ease, and support wellness.

Community Health Center Network they are providing business administrative support for community health centers to and patients.

Kaleida Health is a hospital and physician network in Western New York.

Mississippi State Department of Health is governed by an 11-member board appointed for staggered terms by the Governor. The board approves all rules and regulations of the agency. Mississippi State Department of Health is protecting the health of Mississippians and helping them live longer, healthier, safer lives.

Talbot County Health Department is a Government organization that offers community health, family, and environmental services.

Taking Aim at Cancer in Louisiana brings together professionals from several industries, including healthcare, industry, government, community, advocacy, charity, and others.

Shawnee Health offers primary medical and behavioral health care, dental care, psychiatry, ob/gyn, pharmacy, nutrition counseling, and related social services. Their services include outreach, case management, education, protective services, advocacy, in-home services, and related support services.

Communities First is a non profit that helps communities through economic development, affordable housing and innovative programming.

The MKE Black Grassroots Network for Health Equity represents a collection of black leaders and organizations building partnerships and capacity.

Advocates for Community Wellness is a faith-based health promotion and disease prevention ministry without walls  and is a nonprofit local community organization.

AltaMed has delivered quality care to the underserved communities of Southern California for more than 40 years.AltaMed has delivered quality care to the underserved communities of Southern California for more than 40 years. Accredited by the Joint Commission, AltaMed prides itself in the quality of its care delivered by its premier health care professionals.

Bond Community Health Center is a nonprofit hospital and health care organization that provides nursing training and health care services.

Mark Masselli, along with a small group of Wesleyan University students and community activists, founded Community Health Center. Mark also has played an important leadership role as a founding member of many health and human services initiatives

Erie Family Health Centers is a healthcare organization that deals with medical, dental and behavioral solutions.

Kenosha Community Health Center provides medical services and rehabilitation. Their medical services include serving children from birth to adolescence, providing immunizations, screenings, and regular well-child checkups, including preventative exams and education for parents. They provide behavioral screenings and interventions, chronic disease management, and care coordination. They provide dental services that include general dentistry, fillings, root canals, and much more. In addition, they provide pharmacy services.

R.L. Jones Community Outreach Center focuses on assisting those in need.

Nebraska Cancer Coalition is connecting people and resources to strengthen cancer prevention, detection and quality of life in Nebraska.

Northwestern Memorial Foundation provides funding opportunities to support patient care, research, education and community services.

Odyssey House Louisiana is a non-profit behavioural health care provider that specializes in addiction treatment.

River Valley Family Health Center specializes in medical, dental health, emotional wellness, women's health services, and chronic care.

Refuah Health Center provide high-quality medical services offers Pediatrics, Women's Health, Dental, Podiatry, Behavioral Health, etc.

AtlantiCare is dedicated to creating healthy communities by collaborating with local organisations that share its passion for health. AtlantiCare's primary service offering, Healthcare Delivery, works in tandem with the complementary and strategic service offerings of Health Information and Health Solutions to provide value at every stage of an individual's health (healthy, at-risk, episodically ill or chronically ill). These services, when combined, provide the elements required to achieve, maintain, or return each member of the community to optimal health.

Mountain Park Health Center Use a full-time cancer screening navigator and a variety of evidence-based interventions to effect system change and long-term sustainability. Expected outcomes include increasing the percentage of adults who had appropriate colorectal cancer screening rates to 50% or higher, as well as increasing the number of patients with abnormal test results who were referred for follow-up care in a timely manner.

Mariposa Community Health Center provides medical, dentistry, pharmacy, labs, disease prevention, community and behavioral health services.

Angeles Community Health Center offers primary medical care, dental services, and care coordination. They are committed to providing care in accordance with the ''Patient Centered Medical Home'' concept. When they choose and receive primary medical care from an ACHC provider, the ACHC becomes their medical home.

Community Healthcare Network (CHN) will launch a comprehensive, integrated colorectal cancer Navigation programme with a special emphasis on vulnerable and under-screened patient populations, particularly uninsured patients aged 45-55. The programme will be led by a Cancer Care Manager, whose role will be to ensure the efficacy of colon cancer screening at all CHN health centres.

Access Community Health Centers is a non-profit organization that offers medical and healthcare services.

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.  It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

<div>Exact Sciences is a cancer diagnostic company that provides genomic and companion diagnostic (CDx) tests to guide personalized cancer treatment. Its portfolio includes main products Cologuard and Oncotype DX for screening and therapy selection in colorectal, breast, and prostate cancers. The company develops its cancer screening and genetic tests using stool-based DNA (sDNA) technology.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Exact Sciences Presents New Data on MCED Test

Family Centers

Mayo Clinic

To use Exact Sciences' genomic profiling test, OncoExTra, and their hereditary cancer test, Riskguard, to guide therapeutic decisions, enhance cancer research and advance the development of new diagnostic tests and therapies.

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Axis Community Health

Crossroad Health Center

Chiricahua Community Health Centers

Five Rivers Health Centers

FDRHPO

Harbor Community Health Centers

Generations Family Health Center

CommWell Health

IPHA

The Jane Pauley Community Health Centers

KC CARE Health Center

Ozarks Community Health Center

Rural Wisconsin Health Cooperative

Southwest Community Health Center

The Centers

Wisconsin Collaborative for Healthcare Quality

Lone Star Circle of Care

Marshall Medical Center

Optimus Health Care

Community Health Center Network

Kaleida Health

Mississippi State Department of Health

Talbot County Health Department

Communities First

MKE Black Grassroots Network for Health Equity

Advocates for Community Wellness

AltaMed Health

Bond Community Health Center

Community Health Center

Erie Family Health Centers

Kenosha Community Health Center

R.L. Jones Community Outreach Center

Nebraska Cancer Coalition

Northwestern Memorial Foundation

Odyssey House Louisiana

River Valley Family Health Center

Refuah Health Center

Shawnee Health Service

Taking Aim at Cancer in Louisiana

Access Community Health Centers

Angeles Community Health Center

Mariposa Community Health Center

Mountain Park Health Center

AtlantiCare

Thrive Earlier Detection

Casdin Capital

Section 32 T. Rowe Price

Invus

Lux Capital

Camden Partners

Third Rock Ventures

Perceptive Advisors

Driehaus Capital Management

Rock Springs Capital

Sands Capital Ventures

Brown Advisory

Gamma3

Biomatics Capital Partners

Bain Capital Life Sciences

Cowin Venture

Janus Henderson Investors

Moore Strategic Ventures

Intermountain Ventures

The Blue Venture Fund

Pfizer

Pfizer will team up with Exact Sciences to co-promote Cologuard, a screening test for colorectal cancer

<div>
 
 Exact Sciences is a cancer diagnostic company that provides genomic and companion diagnostic (CDx) tests to guide personalized cancer treatment. Its portfolio includes main products Cologuard and Oncotype DX for screening and therapy selection in colorectal, breast, and prostate cancers. The company develops its cancer screening and genetic tests using stool-based DNA (sDNA) technology.
 
 
 Operating on a B2B2C model, Exact offers its testing services to healthcare providers and hospitals globally. As of March 2023, the company had served over 4 million patients across 90 countries and commercially launched seven testing products.
 
 
 To expand its capabilities in early detection and hereditary cancer testing, Exact has acquired multiple companies including OmicEra Diagnostics and 
 <a href="https://sp-edge.com/updates/7656">
 PreventionGenetics
 </a>
 . Flagship products like Cologuard can detect over 90% of colorectal cancers, providing critical screening insights. Additionally, in August 2022, 
 <a href="https://sp-edge.com/updates/12058">
 MDxHealth 
 </a>
 signed an agreement to acquire Exact's prostate cancer testing operations, Oncotype DX, for USD 100 million.&nbsp;
 
 
 Key customers and partnerships
 
 
 In January 2022, the company partnered with precision medicine company OncXerna Therapeutics to expand its OncXerna&rsquo;s Xerna tumor microenvironment panel as a companion diagnostic to healthcare providers and biopharma companies.&nbsp;
 
 
 Funding and financials
 
 
 The company began trading on Nasdaq in January 2001 under the ticker symbol &ldquo;EXAS,&rdquo; raising USD 56 million at the IPO. 
 <a href="https://sp-edge.com/updates/16539">
 For the year ended December 2022 
 </a>
 , revenue increased 18% YoY to USD 2.1 billion, and the net loss declined by 25% YoY to USD 624 million. In 1H 2023, revenue grew 21.5% YoY to USD 1.2 billion while net losses narrowed by 55.3% YoY to USD 155.2 million. The company increased its revenue guidance for the full-year 2023, expecting revenue in the range of USD 2.44 billion&ndash;2.47 billion, implying a 17%&ndash;19% YoY increase.
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

<div>
 
 Exact Sciences Corp has obtained FDA approval for Cologuard Plus, a stool DNA test designed for adults at average risk of colorectal cancer. The company plans to launch the test with Medicare coverage in 2025. The test aims to increase stability for patients, allowing ample time for sample return. It was assessed in the BLUE-C study, which reported 95% sensitivity to colorectal cancer, 43% sensitivity to advanced precancerous lesions, 94% specificity, and a reduction of false positives by over 30%. The goal of the test is to decrease the need for extra follow-up colonoscopies and aid early detection of colorectal cancer. 

</div>

Exact Sciences

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless